5 Top Gainers In Healthcare Sector (CBM, PRTK, NEOS…)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Cambrex Corporation (CBM)

Cambrex is a manufacturer of Active Pharmaceutical Ingredients and finished dosage forms.

Gained 47.13% to close Wednesday's (Aug.7) trading at $60.00.

News: The Company is all set to be acquired by private equity firm Permira Funds in a deal worth about $2.4 billion, or $60.00 per share in cash.

The transaction is expected to close in the fourth quarter, subject to the approval of shareholders and regulators.

2. Paratek Pharmaceuticals Inc. (PRTK)

Paratek Pharma is a biopharmaceutical company focusing on drugs that target infectious disease and other difficult to treat conditions.

Gained 34.95% to close Wednesday's trading at $4.17.

News: The Company reported financial results and provided an update on corporate activities for the second quarter ended June 30, 2019.

The net loss for the second quarter of 2019 widened to $33.2 million or $1.02 per share from a net loss of $29.8 million or $0.94 per share for the same period in 2018.

Revenue for the second quarter of 2019 soared to $2.04 million from $40 thousand in the year-ago quarter. Revenue earned during the second quarter of 2019 was attributable to net U.S. NUZYRA product sales of $1.7 million and royalty revenue of $0.3 million, which included royalties earned from SEYSARA sales in the U.S.

Looking ahead to full-year 2019, the Company continues to expect NUZYRA U.S. net product sales to be in the range of $10.0 to $13.0 million.

Near-term Catalysts:

-- Topline data from both phase II studies of NUZYRA in urinary tract infections expected in the fourth quarter of 2019. -- Decision in the EU regarding the Marketing Authorization Application for Omadacycline expected in the second half of 2019.

3. Avinger Inc. (AVGR)

Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease, or PAD.

Lost 15.29% to close Tuesday's trading at $1.44.

News: No news

Recent event:

-- On July 31, 2019, the Company reported financial results for the second quarter ended June 30, 2019.

Net loss attributable to common stockholders for the second quarter of 2019 narrowed to $5.55 million or $0.87 per share from $6.64 million or $9.83 per share in the year-ago quarter. Revenue for the recent second quarter increased to $2.32 million from $2.06 million in the year-earlier period.

-- On July 10, 2019, the Company announced that the 50th patient has been enrolled in its global, single-arm, multi-center study evaluating its Pantheris Lumivascular atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. The study, dubbed INSIGHT, is designed to enroll up to 140 patients. -- On June 21, the Company implemented a 1-for-10 reverse stock split of its common stock in order to secure NASDAQ listing.

4. Morphic Holding Inc. (MORF)

Morphic Holding is a preclinical stage biopharmaceutical company developing oral small-molecule integrin therapeutics for serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Gained 23.67% to close Wednesday's trading at $29.05.

News: No news

Recent event:

On June 27, 2019, the Company went public on The Nasdaq Global Market, offering its shares at a price of $15 each.

Pipeline and Near-term Catalysts:

The Company's lead drug candidate is MORF-720, which is being developed in collaboration with AbbVie Inc. (ABBV) for the treatment of idiopathic pulmonary fibrosis.

An Investigational New Drug application for MORF-720 is expected to be filed as early as the end of 2019.

5. Neos Therapeutics, Inc. (NEOS)

Neos Therapeutics is a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms.

The Company has three marketed products - all for the treatment of attention deficit hyperactivity disorder - Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER.

Gained 21.67% to close Wednesday's trading at $1.46.

News: No news

Near-term Catalyst:

-- The Company is slated to report its second-quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019.